title: GEMSP: a new therapeutic approach to multiple sclerosis.
abstract: A new therapeutic approach called Endotherapia (GEMSP) for the treatment of Multiple Sclerosis (MS) is suggested. Endotherapia is the result of an immunopathological strategy addressing chronic incurable diseases with a multifactorial etiology. This approach combines a biomedical evaluation of circulating immunoglobulins directed against specific self-antigens and self-antigens modified by free radicals. GEMSP is a "tailor-made" combination of small molecules (fatty acids, antioxidants, radical scavengers, amino acids) linked to a non-immunogenic linear chain of poly-L.lysine (PLL). Each individual linkage or PLL derivative offers great advantages, such as an increase in the half-life of the active small molecules. GEMSP inhibits brain leukocyte infiltration and abolishes episodes of experimental autoimmune encephalomyelitis. In a clinical trial with 102 MS patients treated with GEMSP Endotherapia, 28% of them showed a worsening of their state; 20% showed a decrease in the progression of the disease; 17% showed disease stabilization; and 35% showed a reversal of the evolution of disease; i.e., an improvement in their disease state. In 72% of the cases, a positive evolution of the state of the MS patients treated with Endotherapia was observed (a decrease or stabilization of disease evolution or an improvement). Endotherapia is very safe and no side-effects were reported for GEMSP. Moreover, GEMSP showed no toxicity either in experimental animals or in humans. It seems that Endotherapia is a promising therapy for MS, with no side-effects, which should be considered in the management of long-term pathologies.
authors.affiliation: Institute for Development of Research on Human Pathology and Therapeutics (IDRPHT), Talence, France. idrpht@wanadoo.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Geffard
authors.forename: Sebastien
authors.initials: S
authors.lastname: Duleu
authors.forename: Alban
authors.initials: A
authors.lastname: Bessede
authors.forename: Valerie
authors.initials: V
authors.lastname: Vigier
authors.forename: Dominique
authors.initials: D
authors.lastname: Bodet
authors.forename: Arturo
authors.initials: A
authors.lastname: Mangas
authors.forename: Rafael
authors.initials: R
authors.lastname: Covenas
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis / Q000097:blood; D001324:Autoantigens / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D018450:Disease Progression; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009103:Multiple Sclerosis / Q000276:immunology* / Q000473:pathology / Q000628:therapy*
chemical_list: D001323:Autoantibodies; D001324:Autoantigens